Vir Biotechnology (NASDAQ:VIR) Announces Earnings Results

Vir Biotechnology (NASDAQ:VIR) released its earnings results on Wednesday. The company reported ($0.57) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.18, FiscalAI reports. The business had revenue of ($0.19) million during the quarter, compared to analysts’ expectations of $0.98 million.

Here are the key takeaways from Vir Biotechnology’s conference call:

• Hepatitis delta phase III results are approaching: Vir expects ECLIPSE 1 top-line data in Q4 2026, followed by ECLIPSE 2 and 3 in Q1 2027. The trials assess its combination regimen in treatment-naïve patients, patients switching from bulevirtide, and a head-to-head comparison with bulevirtide; management believes the program could offer deep viral suppression and less frequent dosing.
• VIR-5500 advanced toward pivotal development: Astellas and Vir say the prostate cancer T-cell engager achieved proof of concept based on combined clinical, safety, pharmacology, and biomarker data, and the FDA granted it fast-track designation for late-line mCRPC. The companies aim to begin multiple phase III studies in 2027, though Vir did not disclose response durability or detailed trial plans.
• Gilead collaboration adds funding and validates Vir’s platform: Vir received $65 million upfront plus a $25 million equity investment at a 30% premium, and is eligible for $45 million in near-term preclinical milestones, up to $1.74 billion in additional milestones, and tiered royalties. Gilead will take responsibility for later development, manufacturing, and commercialization of candidates; milestone and royalty payments are contingent.
• Vir reported $901 million in cash, equivalents, and investments at quarter-end, excluding the $90 million Gilead payment received in October. Management expects its cash to fund operations into the second half of 2028, based on its current operating plan.
• VIR-5818’s data update has been pushed out: Following FDA feedback on the monotherapy arm, Vir plans to add backfill cohorts in a more homogeneous patient population to refine dose and schedule. The study remains ongoing and the data set is incomplete, although combination dose optimization continues.

Vir Biotechnology Stock Up 4.9%

NASDAQ VIR traded up $0.55 during trading on Wednesday, hitting $11.77. The stock had a trading volume of 2,804,641 shares, compared to its average volume of 2,362,147. The company has a market capitalization of $1.99 billion, a PE ratio of -6.33 and a beta of 1.70. The firm has a 50 day moving average price of $10.99 and a 200 day moving average price of $9.53. Vir Biotechnology has a twelve month low of $4.82 and a twelve month high of $12.19.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on VIR shares. Wall Street Zen upgraded Vir Biotechnology from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th. Morgan Stanley set a $25.00 price objective on Vir Biotechnology in a research note on Thursday, August 6th. Raymond James Financial restated a “strong-buy” rating on shares of Vir Biotechnology in a report on Monday, September 28th. Zacks Research downgraded Vir Biotechnology from a “hold” rating to a “strong sell” rating in a research note on Tuesday, October 6th. Finally, HC Wainwright raised their target price on Vir Biotechnology from $20.00 to $22.00 and gave the stock a “buy” rating in a research note on Wednesday, October 7th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $21.86.

Insider Activity

In other news, EVP Vanina de Verneuil sold 2,407 shares of the firm’s stock in a transaction that occurred on Tuesday, November 3rd. The shares were sold at an average price of $11.10, for a total value of $26,717.70. Following the completion of the transaction, the executive vice president owned 110,193 shares of the company’s stock, valued at approximately $1,223,142.30. This trade represents a 2.14% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 2.90% of the company’s stock.

About Vir Biotechnology

Vir Biotechnology, Inc is a clinical-stage immunology company focused on developing medicines to prevent and treat serious infectious diseases and other immune-related conditions. The company uses antibody engineering, immunologic approaches and other technologies to identify and advance therapies designed to harness or modify the immune system.

Vir’s research and development programs have included treatments and vaccines for hepatitis B, human immunodeficiency virus (HIV), influenza and other infectious diseases.